Biodegradable Core-Shell Micro-Particles for Ultrasound Cavitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ultrasound contrast agents (UCAs) are polydisperse, unstable, and have limited half-lives, restricting their ability to sustain cavitation and penetrate deep tissues, which limits their effectiveness in diagnostic imaging and drug delivery, especially for difficult-to-treat diseases.
Innovation Solution
Development of biodegradable core-shell micro-particles with multiple surface cavities, made from polymers like PLGA, that can nucleate cavitation at lower acoustic intensities, remain at the diseased site, and locally release a payload over several days, enhancing both imaging and therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gas-filled microbubbles are used as ultrasound contrast agents, then contrast enhancement is achieved through resonance and echo, but stability is poor due to coalescence and dissolution leading to short half-life
Solution Approach 1:
The patent changes the physical state of the contrast agent from gas-filled microbubbles to solid microparticles with cavitation nuclei. This parameter change transforms the stability mechanism from relying on gas containment (prone to coalescence and dissolution) to solid-state structural stability, dramatically extending half-life while maintaining cavitation capability
Solution Approach 2:
The patent creates composite microparticles combining biodegradable polymer matrices (PLGA, PLA, PCL) with embedded cavitation nuclei. This composite structure provides both the structural stability of solids and the cavitation functionality, resolving the contradiction between stability and cavitation sustainability
2Length of moving object
If solid cavitation agents are used to reach smaller vasculature and penetrate endothelium, then penetration ability is improved, but acoustic intensity requirements increase to vaporize perfluorocarbon droplets
Solution Approach 1:
The patent creates non-uniform microparticles with localized cavitation nuclei embedded within the polymer matrix. This local concentration of cavitation-prone regions allows smaller particles to cavitate efficiently at lower acoustic intensities, as the energy is focused at specific nucleation sites rather than requiring vaporization of entire droplet volumes
Solution Approach 2:
The patent incorporates porous structures and cavitation nuclei within the microparticle matrix, creating regions of reduced density and increased compressibility. These porous regions facilitate cavitation at lower acoustic thresholds, enabling small particles to penetrate vasculature while requiring reduced acoustic power
3Ease of manufacture
If polydisperse commercial lipid-shelled UCAs are used, then manufacturing is simplified, but image quality deteriorates due to heterogeneous echogenicity and resonance frequencies
Solution Approach 1:
The patent employs emulsion-based fabrication methods with controlled solvent evaporation to produce microparticles with narrow size distributions. By controlling emulsion parameters (surfactant concentration, mixing speed, solvent type), the process achieves monodispersity (PDI < 0.1) while maintaining manufacturing feasibility through scalable aqueous processing
Solution Approach 2:
The patent replaces mechanical size-selection methods with chemically-controlled self-assembly during emulsion formation. The polymerization and solvent evaporation processes inherently produce uniform particle sizes, eliminating the need for post-manufacturing size sorting while achieving high monodispersity
4Productivity
If high acoustic intensity is applied to generate inertial cavitation for therapeutic effect, then drug delivery capability is improved, but harmful effects increase due to tissue damage from bubble collapse
Solution Approach 1:
The patent uses biodegradable polymer microparticles as intermediary carriers that protect surrounding tissue from direct cavitation damage. The polymers encapsulate cavitation nuclei and control their activation, allowing localized drug release through controlled degradation rather than violent bubble collapse, thereby maintaining therapeutic efficacy while reducing harmful effects
Solution Approach 2:
The patent employs biodegradable polymers (PLGA, PLA, PCL) that naturally degrade after delivering their therapeutic payload. These temporary carriers perform their function (cavitation-mediated drug delivery) and then safely decompose, eliminating the need for retrieval and preventing long-term accumulation, thus enabling aggressive local therapy without persistent harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These micro-particles provide sustained cavitation, improved contrast enhancement, and targeted drug delivery, reducing the risk of adverse effects while maintaining high-quality imaging at lower mechanical indices, thus acting as effective theranostic agents.
Implementation Method 1
gas bubbles form upon mixing the core-shell micro-particle in a liquid
Implementation Method 2
nucleate cavitation at lower acoustic intensities
Implementation Method 3
biodegradable polymer with at least two or more surface cavities
Data Source
AI summary
Abstract: The present invention provides a core-shell micro-particle comprising a biodegradable polymer with at least two or more surface cavities. The present invention also provides use of the core-shell micro-particle in drug delivery, contrast enhancement, subharmonic imaging enhancement, theranostics, and/or any combination of the aforementioned applications.